Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Experimentally Calibrated Simulations Reveal Optimized Dosing Strategies for [ 177 Lu]Lu-PSMA-617 Therapy (EANM 2026) - Sep 29, 2026 - Abstract #EP-0058; "The integration of experimentally informed dose-rate kernels with a calibrated tumor growth and dose-response model enables systematic in silico optimization of treatment regimens. These findings highlight the potential of simulation-based approaches to guide the design of more effective, biologically informed dosimetry strategies." 
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
M. Ryhiner 1, 2; I. Fajnorova 2; I. C. Azrour 2; A. M. Fakharpour 2; J. Czernin 2; A. Rominger 1; C. A. Meyer 2; C. E. Mona 2; K. Shi 1
 
Sep 29, 2026
 
Prev Next